Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– a...
Redeye ser positivt på fredagens viktiga besked om att Lecanemab, under det kommersiella namnet Leqe...
During the quarter, Audientes expanded its network of collaboration partners, and the company have i...
WntResearch, som genomför en fas 2-studie med läkemedelskandidaten Foxy-5 för patienter som drabbats...
Redeye is encouraged by the continuous positive news flow related to Catalyst, and we embrace the ju...
Redeye resumes its coverage and comments on the outcome of Acarix’s rights issue.
Redeye has revisited our case after the announced Telia framework agreement.
Bricknode announced on Tuesday, January 3rd, that a fund management company (“the Client”) has chose...
Redeye ceases its coverage of aXichem due to the end of the contractual period.
Redeye leaves a short comment following Alzinova’s announcement earlier today.
Redeye considers Mitazalimab’s results in the first interim readout of the phase II trial presented ...
Redeye ceases its coverage of Calmark due to the end of the contractual period.
Redeye is encouraged by the FDA approval for Episurf Medical’s patellofemoral system product and arg...
Redeye comments on Alligator's announcement of the initiation of a second bispecific program within ...
Ascelia announced that 65 patients has now completed the SPARKLE study.
Calliditas partner in China (including South Korea, Hong Kong, Macau, Taiwan and Singapore) Everest ...
In this episode, we are joined by Jessica Martinsson, COO of Sprint Bioscience, alongside European p...
Consti is the leading renovation construction company in Finland.
Divests its Russian operations, gains SEK 75 per share We had no value on Russia for '23e and beyon...
MTHH has decided to initiate a sales process for Scandi Byg Market has increasingly been questioning...
